We build the medicines we wish existed

Dr. Hendrik Dietz founded CPTx in 2021 to carry forward 15 years of research and development of single stranded DNA programming and manufacturing processes. Committed to transforming theoretical ideas into practical applications, at CPTx he has assembled the talent and infrastructure needed to advance this work to solve deep challenges in the field of genetic medicines. Prior to CPTx, Dr. Dietz held faculty and research positions at Technical University of Munich (TUM) and Harvard School of Medicine, and is the recipient of numerous honors and awards, including the Gottfried Wilhelm Leibniz Prize. He received a PhD in Physics from TUM.

As Chief Operating Officer of CPTx, Dr. Grant Boldt leads the company’s innovation-driven R&D in next-generation genetic medicines, guiding programs from discovery and design through delivery, manufacturing, and preparation for first-in-human studies. His role integrates scientific vision with organizational leadership to advance pioneering approaches in genetic medicine. Dr. Boldt joined CPTx in early 2024, bringing decades of experience at the intersection of biotechnology R&D and pharmaceutical manufacturing strategy. He previously served as Vice President of Research Pharmaceuticals at Sigma-Aldrich, Senior Vice President and Business Unit Head of Biologics at Lonza, and Executive Vice President of Biologics at Avantor. Over the course of his career, he has authored numerous scientific publications and patents and has been a frequent speaker, with a consistent focus on translating innovative science into transformative therapeutic applications. Dr. Boldt received his PhD in Chemical Biology from Scripps Research Institute, CA, US.

McDavid Stilwell became Chief Financial Officer in early 2025 and brings more than 25 years of experience in finance, corporate development, investor relations and communications. He was previously CFO at Coherus Biosciences during a period in which the company launched multiple new products into the U.S. market. Earlier he held senior leadership roles at Sangamo Therapeutics, Orexigen Therapeutics, and GTx, Inc. Prior to entering the biopharmaceutical industry, he was senior analyst at Shadwell Capital, a hedge fund, and he also worked several years as a journalist. His cross-functional expertise is critical to continuing to build the internal and external foundation of the company. He received a MBA from Harvard Business School.

Dr. Oschmann is a seasoned executive with extensive experience in biopharma, life science tools, and specialty chemicals. He was the Chairman and CEO at Merck KGaA, where he spearheaded the company’s transformation into a leading science and technology firm. Under his leadership, Merck introduced two blockbuster products in neuroscience and oncology. Following his seven-year tenure at Merck, he became chairman of UCB and AiCuris, and he currently works as a partner at the private equity firm Armira. His earlier career included senior roles at Merck & Co. (MSD), including President of Emerging Markets and President of Europe/Middle East/Africa, after starting in R&D at MSD and working in research at the International Atomic Energy Agency. He earned a doctorate (DVM) from the University of Munich.